# Miraki Innovation

Miraki Innovation is a Private Equity based in Cambridge, United States.

## Overview

- **Organization type:** Private Equity
- **Headquarters:** Cambridge, United States
- **Region:** North America
- **Address:** Cambridge, MA, United States
- **Founded:** 2005
- **Assets under management:** Undisclosed
- **Website:** miraki.co
- **LinkedIn:** linkedin.com/company/miraki-innovation

## Regulatory record

- **Reports private funds:** No

## About

Miraki Innovation invests in technological breakthroughs with global potential, focusing on healthcare challenges and market opportunities. The firm identifies technological solutions to match these problems, producing results. Miraki Innovation has made 2 investments, including a Series E - III investment in Noveome Biotherapeutics on April 23, 2025, and has 1 portfolio exit, BOA Biomedical, on September 10, 2019.

## Sectors

- AI/ML
- Digital Health
- Enterprise Software
- Robotics & Automation
- Industrial Tech

## People

- Sameer Sabir — Founder

## Questions

### Which investment stages does Miraki Innovation typically target?

The firm writes checks from seed and start-up phases through late-stage growth and pre-IPO rounds. This lifecycle coverage — from first institutional capital to public-market crossover — is characteristic of a permanent-capital vehicle rather than a traditional fixed-life venture fund, though Miraki has not disclosed its specific fund structure.

### Which sectors does Miraki Innovation explicitly avoid?

Miraki does not publish a formal exclusion list, but its mandate is concentrated on asset-heavy, science-risk categories: artificial intelligence, robotics, life sciences, and industrial technology. Consumer internet, brand-driven commerce, and lightly regulated financial products do not fit its technical-diligence model and are generally absent from firms with this scientific-sourcing architecture.

### What is Miraki Innovation's known posture on co-investments alongside external GPs?

Miraki lists co-investment among its strategies, meaning it is structurally willing to participate in syndicates led by other institutional GPs. This is common for firms that do not seek board control but want exposure to a specific technology vertical or founding team. The terms and typical check sizes for such co-investments have not been publicly disclosed.

## Related profiles

- [MIR Capital](https://altss.com/profile/mir-capital)
- [Miralta Capital](https://altss.com/profile/miralta-capital)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/miraki-innovation

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology